Jeremy Levin

Last updated

Jeremy Levin
LevinJM Headshot FINAL 20161028.jpg
Born1954 (age 69–70)
South Africa
NationalityAmerican
Alma mater Oxford University, Cambridge University
Occupation(s)Chairman and CEO, Ovid Therapeutics Inc
SpouseMargery Feldberg (m. 1987)
Children2

Jeremy Levin (born 1954) is a South African-born biopharmaceutical executive and medical doctor. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry [1] and, in 2023, was awarded the Lifetime Achievement Award at the 19th Annual Scrip Awards in London. [2]

Contents

Biography

Jeremy Levin was born in South Africa, where his family had a farm, De Hoek Farm, in Piketberg, Western Cape. His father Archie (died 1977) was a political journalist. His mother, Leah Levin (died 2024), was an honorary doctorate from the University of Essex [3] and was appointed OBE for services to international human rights in 2001. She served on the board of the United Nations Association, Anti-Slavery and International Alert, and was director of JUSTICE from 1982 to 1992. [4] Ms. Levin also served on Boards of Redress, Readers International, and the International Journal of Human Rights. [5] She is the author of UNESCO's "Human Rights: Questions and Answers," one the world's widely disseminated books on human rights. [6] He is the brother of David and sister Michal Levin. [7]

Following the Sharpeville massacre, his family left South Africa and moved to live in Salisbury, Rhodesia (now Harare, Zimbabwe).[ citation needed ] In 1965, his father was given a day to leave the country.[ citation needed ] The family arrived in Britain knowing nobody, settling in London. He attended Holland Park School. [8] Following graduating from high school, Levin went to Wadham College, University of Oxford, where he gained a First Class BA Honors degree in zoology, and a Master of Arts (MA) and doctorate (DPhil) in cell biology and chromatin structure from the Oxford University's Sir William Dunn School of Pathology. He subsequently received an MB, BChir degree (Bachelor of Medicine, Bachelor of Surgery) from the University of Cambridge.

Prior to his business experience Levin practised medicine, working at university hospitals including the Hammersmith Hospital in London, Groote Schuur in Cape Town, South Africa and Hôpitaux universitaires de Genève, Geneva, Switzerland.

In 1986, Levin came to America where he has worked in the biopharmaceutical industry in progressively senior positions. While living in Washington, D.C. Levin met Margery Feldberg (daughter of Stanley Feldberg, co-founder of TJX Companies). They married in September 1987 and have two daughters. [9] He has lived in New Milford, Connecticut since the 1980s, where he and his wife own De Hoek Farm, raising Black Angus cows. [10]

Business career

Levin is the chairman and CEO of Ovid Therapeutics Inc., a company dedicated to meaningfully improve the lives if people and families affected by neurological diseases. [11] [12] Ovid is developing a next generation of targeted small molecule therapies that seek to reduce seizures and deliver improved safety and tolerability. Ovid’s current product development programs are focused on restoring neuronal homeostasis, targeting conditions such as epilepsy and cerebral cavernous malformation.

Prior to joining Ovid, Levin served as president and CEO of Israel's Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), one of the world's largest pharmaceutical companies. [13] [14] Previously, he was a member of the executive committee of Bristol-Myers Squibb (NYSE:BMY), where he had global responsibilities for strategy, alliances and transactions. [15] In this role, he devised and led BMY's “String of Pearls” business development strategy. This strategy helped drive the transformation of BMY, particularly following the acquisition by Levin of Medarex Inc. in July 2009, which positioned BMY as a leader in immunooncology. [16] [17] [18] Prior to this, Levin was head of global business development and strategic alliances at Novartis (NYSE: NVS), and previously served as chairman and CEO of Cadus Pharmaceuticals, Inc. [19] [20]

Levin currently serves as the chairman of the board of OPTHEA and is on the board of directors at Graviton and Gensaic. [21] [22] [23] Levin was elected as the Chairman of the Biotechnology Innovation Organization (BIO) in 2019, and is currently Chariman Ameritus. [24]

Levin frequently speaks at biopharmaceutical conferences, where his focus is driving deeper and more direct relationships between companies and patients, ensuring innovation in the biopharmaceutical industry, expanding the role of mergers and acquisitions, globalising the biopharmaceutical industry, and propelling interface of the digital health and biopharmaceutical industries and leadership. In his speech at the Kellogg-Recanati International Executive MBA Program in Tel Aviv, Levin addressed the importance of leadership, innovation, and global collaboration. His remarks emphasized the critical role of emerging leaders in shaping the future of healthcare and technology. [25] [26] Levin was also invited to speak as part of the Keck Graduate Institute’s (KGI) 25 Years of Innovation Speaker Series. During his talk, Levin discussed “the Innovation Symphony”, reflecting on the transformative advances in biotech over the past quarter-century and values that are crucial for the future of biomedical innovation. [27]

Levin authored the first-ever book on the biotechnology industry's response to the COVID-19 pandemic, titled Biotechnology in the Time of Covid-19:Commentaries from the Front Line. [28] . The book features a collection of commentaries from industry leaders about their experiences during the pandemic, emphasizing the importance of biotechnology in responding to global health crises.

Social and Political Activism

Levin is a social and political activist. He has been an outspoken advocate for developing and sustaining democracy in the United States, Israel, and other parts of the world. He has used his platform to call for the protection of democratic values and institutions globally. Levin has been an active voice against Russia's invasion of Ukraine, speaking out in favor of supporting Ukraine and its people during the conflict. He has advocated for global action to defend democracy and human rights in the region. Levin has also advocated against Hamas, particularly in relation to its attacks on Israel.

Levin has been an advocate for women's rights, particularly in the healthcare sector. He was notably involved in the legal battle surrounding mifepristone, a medication used in medical abortions, when the case reached the U.S. Supreme Court. His stance on protecting access to reproductive healthcare has been highlighted in media outlets like npr. [29]

Awards and recognition

Levin is the recipient of a number of awards, including:

Related Research Articles

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA, based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East. It was closed in 2019 after its acquisition by Bristol Myers Squibb.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

Medarex was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb.

<span class="mw-page-title-main">Sartorius AG</span> German pharmaceutical company

Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest stock market index. As a leading partner to the biopharmaceutical research and industry, Sartorius supports its customers in the development and production of biotech drugs and vaccines - from the initial idea in the laboratory to commercial production. Sartorius conducts its operating business in the two divisions Bioprocess Solutions and Lab Products&Services. The divisions bundle their respective businesses according to the same application areas and customer groups. The divisions share some of the infrastructure and central services.

China has seen double-digit growth in its biotechnology industry and has gone from being one of the slowest to one of the fastest nations in the adoption of new biotechnologies. The biotech sector is seen in China and internationally as a core area of national scientific and economic development. The main national biotech body in the country is the China National Center for Biotechnology Development. The CNCBD is an organization established on November 3, 1983, under the Ministry of Science and Technology with the approval of the State Council. CNCBD is the sole national center to coordinate and implement the national S&T program in Biotechnology and Health.

Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis.

<span class="mw-page-title-main">Samsung Biologics</span> South Korean biotechnology company

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

Ryan Bethencourt is an American scientist, entrepreneur, and biohacker best known for his work as co-founder and CEO of Wild Earth, Partner at Babel Ventures and cofounder and former Program Director at IndieBio, a biology accelerator and early stage seed fund. Bethencourt was head of life sciences at the XPRIZE foundation, a co-founder and CEO of Berkeley Biolabs, a biotech accelerator, and Halpin Neurosciences, an ALS therapeutics-focused biotech company. Bethencourt co-founded Counter Culture Labs, a citizen science nonprofit, and Sudo Room, a hacker space based in downtown Oakland, California.

<span class="mw-page-title-main">Juno Therapeutics</span> American biopharmaceutical company

Juno Therapeutics Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

<span class="mw-page-title-main">Biotechnology Innovation Organization</span> Biotechnology advocacy association

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.

N. Anthony Coles is an American physician, biotechnology entrepreneur, and pharmaceutical leader. Since 2018, Coles has served as chair of the board of directors for Cerevel Therapeutics.

References

  1. ↑ "Jeremy Levin – The 25 most influential people in biopharma today | FierceBiotech". www.fiercebiotech.com. Retrieved 17 June 2018.
  2. ↑ https://scrip.citeline.com/SC149400/Scrip-Awards-Lifetime-Achievement-Winner-Jeremy-Levin-Urges-Pharma-To-Put-Humanity-First
  3. ↑ "Honorary Graduates – Honorary Graduates – University of Essex". www.essex.ac.uk. Retrieved 17 June 2018.
  4. ↑ "Leah Levin; a human rights defender of the first rank". Hans Thoolen on Human Rights Defenders. 7 October 2013. Retrieved 17 June 2018.
  5. ↑ "Who we are" . Retrieved 18 May 2021.
  6. ↑ "Human rights: questions and answers" (PDF). Retrieved 18 May 2021.
  7. ↑ Martinson, Jane (6 October 2006). "Media anti-mogul who shuns TV and newspapers". The Guardian. Guardian News & Media Ltd. Retrieved 28 November 2021.
  8. ↑ Martinson, Jane (6 October 2006). "Media anti-mogul who shuns TV and newspapers". The Guardian. Guardian News & Media Ltd. Retrieved 28 November 2021.
  9. ↑ Engel, Currie. "'A gift and blessing': New Milford doctor and businessman helps town leaders combat COVID-19". NewsTimes. Hearst Connecticut Media. Retrieved 28 November 2021.
  10. ↑ Engel, Currie. "'A gift and blessing': New Milford doctor and businessman helps town leaders combat COVID-19". NewsTimes. Hearst Connecticut Media. Retrieved 28 November 2021.
  11. ↑ "Ovid Therapeutics Appoints Dr. Jeremy Levin as Chief Executive Officer | OvidRx". OvidRx. 16 April 2015. Archived from the original on 28 August 2016. Retrieved 17 June 2018.
  12. ↑ Tirrell, Meg (16 April 2015). "Former Teva CEO's new gig at Ovid Therapeutics". CNBC. Retrieved 17 June 2018.
  13. ↑ "Jeremy Levin named new Teva CEO". Ynetnews. 1 February 2012. Retrieved 17 June 2018.
  14. ↑ "Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy News". The Economic Times. Retrieved 18 May 2021.
  15. ↑ "Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing | BMS Newsroom". news.bms.com. Archived from the original on 5 February 2017. Retrieved 17 June 2018.
  16. ↑ N, Shankar (30 August 2012). "Bristol-Myers Squibb: The Asset Problem And The String Of Pearls". Seeking Alpha. Retrieved 29 June 2018.
  17. ↑ "Teva's Levin May Boost Branded Drugs as Copaxone Threat Looms". Bloomberg.com. 2 January 2012. Retrieved 17 June 2018.
  18. ↑ "Bristol-Myers Squibb to Acquire Medarex | BMS Newsroom". news.bms.com. Archived from the original on 27 August 2016. Retrieved 17 June 2018.
  19. ↑ "For Novartis, Alnylam Deal Fulfills Long-Term Plan to Partner on RNAi Drug Development". GenomeWeb. Retrieved 17 June 2018.
  20. ↑ "SEC Info – Cadus Corp – 'S-8 POS' on 12/23/97". www.secinfo.com. Retrieved 17 June 2018.
  21. ↑ https://ir.opthea.com/news-releases/news-release-details/opthea-appoint-dr-jeremy-levin-chairman-board
  22. ↑ https://gravitoncorp.com/company
  23. ↑ https://startupexchange.mit.edu/watch/42823-korea-gensaic
  24. ↑ "BIO Elects Dr. Jeremy Levin as New Board Chair | BIO". www.bio.org. Retrieved 18 May 2021.
  25. ↑ "Jeremy Levin – Physiome Sciences – The Wall Street Transcript". The Wall Street Transcript. 12 October 2001. Retrieved 17 June 2018.
  26. ↑ חברת טוגדר (21 November 2013), Jeremy Levin – full speech at the Kellogg-Recanati International EMBA 2013 , retrieved 17 June 2018
  27. ↑ https://www.youtube.com/watch?v=3n9zrNpApLY
  28. ↑ https://www.amazon.com/Biotechnology-Time-COVID-19-Commentaries-Front/dp/0795352972
  29. ↑ https://www.npr.org/2024/03/26/1240006204/fda-supreme-court-abortion-pill-mifepristone
  30. ↑ "Jeremy Levin – The 25 most influential people in biopharma today | FierceBiotech". www.fiercebiotech.com. Retrieved 17 June 2018.
  31. ↑ "British Expats in Life SciencesBritish Expats in Life Sciences | Strengthening Our United Kingdom of Life Scientists". belsgroup.com. Retrieved 17 June 2018.
  32. ↑ "ASU Now". ASU Now. Retrieved 17 June 2018.
  33. ↑ http://cednc.org/wp-content/uploads/2014/07/Life-Science-Conference-2014-Book_FINAL.pdf%5B%5D
  34. ↑ 2014 - Spring Schedule Archived 2015-04-24 at archive.today
  35. ↑ https://scrip.citeline.com/SC149400/Scrip-Awards-Lifetime-Achievement-Winner-Jeremy-Levin-Urges-Pharma-To-Put-Humanity-First
  36. ↑ https://www.pharmavoice.com/news/red-jacket-jeremy-levin-ovid-teva/697800/
  37. ↑ https://www.pharmavoice.com/news/jeremy-m-levin-pv100-legacy-leaders/629262/
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.